

# Febrile UTIs in Practice

AAP Guidelines and New Evidence

Jennifer Chapman, MD  
Kavita Parikh, MD, MSHS  
Shilpa Patel, MD, MPH

Emergency Medicine  
Hospitalist Medicine  
Emergency Medicine

June 15, 2016  
Future of Pediatrics Conference



**No Disclosures**



**Children's National**™

# Learning Objectives

- 1) To review the 2011 AAP Guidelines
- 2) To review recent evidence in the management of febrile UTIs in children
- 3) To apply the guidelines and recent evidence



Case 1:  
5 month  
old male



Case 2:  
7 week  
old  
female



Case 3:  
2 yo  
female  
with  
recurrent  
UTI

# Case 1

- 5 mo Caucasian, circumcised, male
- T40 for 48 hours
- Well-appearing with defervescence and no localizing signs on exam
- Last immunizations 3 weeks ago





Do we test?




What is the  
risk of UTI in  
febrile  
children?

Does it differ  
by age,  
gender, or  
race?






>



>




AGE

Risk Factors for UTI

GENDER

RACE



Circumcised ~1 %  
**NOT** Circumcised ~ 6%





## Infant GIRLS : Individual Factors

- Race: White
- Age: <12 months
- Temperature:  $\geq 39^{\circ}\text{C}$
- Fever:  $\geq 2$  days
- Absence of another source of infection

## Probability of UTI

## # of Factors Present

$\leq 1\%$

No more than 1

$\leq 2\%$

No more than 2

## Infant BOYS: Individual Factors

- Race: Nonblack
- Temperature:  $\geq 39^{\circ}\text{C}$
- Fever: >24 hours
- Absence of another source of infection

## Probability of UTI

## # of Factors Present

### Circumcised

No

Yes

$\leq 1\%$

\*

No more than 2

$\leq 2\%$

None

No more than 3

American Academy  
of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN™

Kenneth B. Roberts, MD,  
FAAP  
AAP Webinar



## Infant GIRLS : Individual Factors

- Race: White
- Age: <12 months
- Temperature:  $\geq 39^{\circ}\text{C}$
- Fever:  $\geq 2$  days
- Absence of another source of infection

## Probability of UTI

## # of Factors Present

$\leq 1\%$

No more than 1

$\leq 2\%$

No more than 2

## Infant BOYS: Individual Factors

- Race: Nonblack
- Temperature:  $\geq 39^{\circ}\text{C}$
- Fever: >24 hours
- Absence of another source of infection

## Probability of UTI

## # of Factors Present

### Circumcised

No

Yes

$\leq 1\%$

\*

No more than 2

$\leq 2\%$

None

No more than 3

American Academy  
of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN™

Kenneth B. Roberts, MD,  
FAAP  
AAP Webinar

## How do we make the diagnosis?

- 10K?
- 50K?
- 100K?
- LE? Nitrites?  
WBC count?

## How do we test?

- Urinalysis
- Urine Culture
- Bag vs Catheter



# GUIDELINE

American Academy  
of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN™

**Diagnosis = Positive Culture + Positive UA:**

Positive culture:  $\geq 50,000$  cfu/mL of uropathogen

AND


Positive urinalysis

- ✓ Evidence quality: C
- ✓ Recommendation



Children's National™


# Where Did 100,000 Come From?



Kass E. Asymptomatic infections of the urinary tract. *Trans Assoc Am Phys.* 1956;69:56-64

# TESTING

What is a positive UA?




# Urinalysis suggestive of infection – 2011 Guidelines

**TABLE 1** Sensitivity and Specificity of Components of Urinalysis, Alone and in Combination

Test	Sensitivity (Range), %	Specificity (Range), %
Leukocyte esterase test	83 (67–94)	78 (64–92)
Nitrite test	53 (15–82)	98 (90–100)
Leukocyte esterase or nitrite test positive	93 (90–100)	72 (58–91)
Microscopy, WBCs	73 (32–100)	81 (45–98)
Microscopy, bacteria	81 (16–99)	83 (11–100)
Leukocyte esterase test, nitrite test, or microscopy positive	99.8 (99–100)	70 (60–92)

# 3-24mo Febrile Boy





**TABLE 4** Urine Culture and UA Results in Infants With Bacteremia and Urine Culture Growth With <50 000 CFU/mL of the Same Organism

Organism	<i>n</i>	Urine Culture Growth, CFU/mL			UA Result			
		<10K	10–25K	25–50K	Pyuria >3 WBC/HPF	Any Bacteria	Any LE	Any Nitrites
<i>E coli</i>	12	1	7	4	11/12	10/11 <sup>a</sup>	12/12	2/12
GBS	5	4	1	0	1/5	0/4 <sup>a</sup>	0/5	0/5
<i>Enterococcus faecalis</i>	1	1	0	0	0	ND	0	0
GAS	1	1	0	0	ND	ND	0	0

GAS, Group A *Streptococcus*; ND, not done.

<sup>a</sup> Denominators reflect that not all infants had UA bacteria results.

# TESTING

Is there only 1 way



## Pediatrics

June 2016

# Two-Step Process for ED UTI Screening in Febrile Young Children: Reducing Catheterization Rates

Jane M. Lavelle, Mercedes M. Blackstone, Mary Kate Funari, Christine Roper, Patricia Lopez, Aileen Schast, April M. Taylor, Catherine B. Voorhis, Mira Henien, Kathy N. Shaw

---

June 20, 2016

# Bag UA appropriate to screen for UTI

- Single center, ED based QI study
- Two step process to screen for UTI
  - Bag UA →  
IF Udip + (mod/lg LE OR nitrites) → Ucath + Abx
- 6mo-24 mo with concern for UTI
- No difference in culture positivity rates
- No difference in return visits
- No difference in length of stay

## DIAGNOSIS

## TESTING

### CLINICAL PRACTICE GUIDELINE

## Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months

SUBCOMMITTEE ON URINARY TRACT INFECTION, STEERING COMMITTEE ON QUALITY IMPROVEMENT AND MANAGEMENT

#### KEY WORDS

urinary tract infection, infants, children, vesicoureteral reflux, voiding cystourethrography

#### ABBREVIATIONS

SPA—suprapubic aspiration  
AAP—American Academy of Pediatrics  
UTI—urinary tract infection  
RCT—randomized controlled trial  
CFU—colony-forming unit  
VUR—vesicoureteral reflux  
WBC—white blood cell  
RUS—renal and bladder ultrasonography  
VCUG—voiding cystourethrography

This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

The recommendations in this report do not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

All clinical practice guidelines from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

[www.pediatrics.org/cgi/doi/10.1542/peds.2011-1550](http://www.pediatrics.org/cgi/doi/10.1542/peds.2011-1550)

doi:10.1542/peds.2011-1550

PEDIATRICS (ISSN Numbers: Print, 0031-4002; Online, 1098-4275).

Copyright © 2011 by the American Academy of Pediatrics

**COMPANION PAPER:** Companions to this article can be found on pages 572 and e749, and online at [www.pediatrics.org/cgi/doi/10.1542/peds.2011-1818](http://www.pediatrics.org/cgi/doi/10.1542/peds.2011-1818) and [www.pediatrics.org/cgi/doi/10.1542/peds.2011-1552](http://www.pediatrics.org/cgi/doi/10.1542/peds.2011-1552).

### abstract

FREE

**OBJECTIVE:** To revise the American Academy of Pediatrics practice parameter regarding the diagnosis and management of initial urinary tract infections (UTIs) in febrile infants and young children.

**METHODS:** Analysis of the medical literature published since the last version of the guideline was supplemented by analysis of data provided by authors of recent publications. The strength of evidence supporting each recommendation and the strength of the recommendation were assessed and graded.

**RESULTS:** Diagnosis is made on the basis of the presence of both pyuria and at least 50 000 colonies per mL of a single uropathogenic organism in an appropriately collected specimen of urine. After 7 to 14 days of antimicrobial treatment, close clinical follow-up monitoring should be maintained to permit prompt diagnosis and treatment of recurrent infections. Ultrasonography of the kidneys and bladder should be performed to detect anatomic abnormalities. Data from the most recent 6 studies do not support the use of antimicrobial prophylaxis to prevent febrile recurrent UTI in infants without vesicoureteral reflux (VUR) or with grade I to IV VUR. Therefore, a voiding cystourethrography (VCUG) is not recommended routinely after the first UTI; VCUG is indicated if renal and bladder ultrasonography reveals hydronephrosis, scarring, or other findings that would suggest either high-grade VUR or obstructive uropathy and in other atypical or complex clinical circumstances. VCUG should also be performed if there is a recurrence of a febrile UTI. The recommendations in this guideline do not indicate an exclusive course of treatment or serve as a standard of care; variations may be appropriate. Recommendations about antimicrobial prophylaxis and implications for performance of VCUG are based on currently available evidence. As with all American Academy of Pediatrics clinical guidelines, the recommendations will be reviewed routinely and incorporate new evidence, such as data from the Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) study.

**CONCLUSIONS:** Changes in this revision include criteria for the diagnosis of UTI and recommendations for imaging. *Pediatrics* 2011;128:e585–610

Culture >50K  
AND  
UA (+LE/nitrates OR  
WBC)

Two step method,  
using bag UA to  
screen is  
appropriate





Case 1:  
5 month  
old male



Case 2:  
7 week  
old  
female



Case 3:  
2 yo  
female  
with  
recurrent  
UTI

## Case 2

- 7 week old female
- T 38.5
- No other symptoms
- Well appearing





## Case 2

- Partial sepsis work-up completed and UA is positive with WBC and mod LE
- Is an LP needed before starting treatment?
- Infant is well appearing and has no other medical history.



# Risk of meningitis in a 'low risk' 29-60 day old infant with UTI is rare

- Schnadower et. al, Pediatrics 2010
- Retrospective, 20 centers, n=1895
- 29-60 day old with cx proven febrile UTI

# Predicting Low Risk

- 4 Factors to Predict Low Risk
    - not clinically ill
    - no underlying disease
    - ANC > 1500
    - band count < 1250
- consider discharge home after single dose of IV or IM Ceftriaxone with 24 hour follow-up OR short observation period

*If any concern for inability to follow-up consider admission*

## Case 2 -- revised



- Now let's assume our infant is 10 weeks old and has received her 2 mo vaccinations.

How do  
we treat?



Follow-  
up?

Do we  
admit?





# GUIDELINE

American Academy  
of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN™

## Oral and IV Antibiotics equally efficacious (2-24 mo)

- ✓ Evidence quality: A
- ✓ Strong recommendation

Take into account:

- ✓ Ability to tolerate oral abx
- ✓ “toxicity”
- ✓ Any concern regarding adherence



Children's National™



# GUIDELINE

American Academy  
of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN™

## Antibiotic choice based on local sensitivity

- ✓ Evidence quality: A
- ✓ Strong recommendation



Children's National™



# Abx of Choice: 2<sup>nd</sup> -3<sup>rd</sup> Gen Cephalosporin

- ✓ *E. coli* (75-90%)
  - 60% of *E. coli* isolates are susceptible to TMP/SMZ
  - 41% susceptible to ampicillin
  - 93% susceptible to second generation cephalosporins
- ✓ *Enterococcus*
  - 100% susceptible to ampicillin
- ✓ *Klebsiella*, *GBBS*...





# GUIDELINE

American Academy  
of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN™

Duration of Abx: 7-14 days

- ✓Evidence quality: B
- ✓Recommendation



Children's National™

## Case 2 -- continued

- Infant is in your office for follow up at 48 hours.
- Doing well, fevers improving.
- Will you complete any imaging for first time UTI?



# GUIDELINE

American Academy  
of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN™

## Renal/Bladder Ultrasound on all infants

- ✓Evidence quality: C
- ✓Recommendation

### WHY?

- Yield of abnormal findings: 12–16%
- Permanent renal damage (1 year later)
  - Sensitivity: 41%
  - Specificity: 81%

### WHEN?

IF ill and not improving then within first 48 hours  
IF improving then, if done, better done > 48 hours



Children's National™

## DIAGNOSIS

### CLINICAL PRACTICE GUIDELINE

## Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months

WORKING GROUP ON URINARY TRACT INFECTIONS, SYSTEMIC  
EFFECTS ON QUALITY IMPROVEMENT AND MANAGEMENT

#### KEY WORDS

urinary tract infection, urinary tract, urologic, urinary tract infection, urinary tract infection

#### ABBREVIATIONS

AAFP = American Academy of Pediatrics  
AAP = American Academy of Pediatrics  
ACIP = American Academy of Pediatrics  
CDC = Centers for Disease Control and Prevention  
EHR = electronic health record  
HMO = health maintenance organization  
IUD = intrauterine device  
UTI = urinary tract infection

The document is copyrighted and published by the American Academy of Pediatrics and its Board of Directors. All authors have the right to control any subsequent use of the document. The American Academy of Pediatrics and its Board of Directors have the right to control any subsequent use of the document. The American Academy of Pediatrics and its Board of Directors have the right to control any subsequent use of the document.

The recommendations in this document are based on a review of the current evidence and a consensus of the members of the working group. The recommendations are intended to provide a standard of care for the management of urinary tract infection in febrile infants and children 2 to 24 months of age.

All clinical practice guidelines published by the American Academy of Pediatrics are subject to periodic review and revision. The recommendations in this document are subject to periodic review and revision.

[www.aap.org/pediatrics/clinical-practice-guidelines](http://www.aap.org/pediatrics/clinical-practice-guidelines)

DOI: 10.1542/2014-0000

PEDIATRICS (ISSN 0031-9155) Copyright © 2014 by the American Academy of Pediatrics

Copyright © 2014 by the American Academy of Pediatrics

DISCLAIMER: This document is copyrighted by the American Academy of Pediatrics. It is intended for use by the American Academy of Pediatrics and its Board of Directors. All other rights are reserved. The American Academy of Pediatrics and its Board of Directors have the right to control any subsequent use of the document.

**OBJECTIVE:** To review the American Academy of Pediatrics practice parameters regarding the diagnosis and management of urinary tract infections (UTIs) in febrile infants and young children.

**METHODS:** Analysis of the medical literature published since the last version of the guideline was supplemented by analysis of data provided by authors of recent publications. The strength of evidence supporting each recommendation and the strength of the recommendations were assessed and graded.

**RESULTS:** Diagnosis is made on the basis of the presence of pyuria and at least 60,000 colonies per mL of a single uropathogenic organism in an appropriately collected specimen of urine. After 2 to 4 days of antimicrobial treatment, clinical follow-up monitoring should be maintained to permit prompt diagnosis and treatment of recurrent infections. Ultrasonography of the kidneys and bladder should be performed to detect anatomic abnormalities. Data from the most recent 4 studies do not support the use of antimicrobial prophylaxis to prevent febrile recurrent UTI in infants without vesicoureteral reflux (VUR) or with grade 1 to 2 VUR. Therefore, a voiding cystourethrogram (VCUG) is not recommended routinely after the first UTI. VCUG is indicated if renal and bladder ultrasonography reveals hydronephrosis, scarring, or other findings that would suggest either high-grade VUR or obstructive uropathy and in other atypical or complex clinical circumstances. VCUG should also be performed if there is a recurrence of a febrile UTI. The recommendations in this guideline do not indicate an exclusive course of treatment or serve as a standard of care; variations may be appropriate. Recommendations about antimicrobial prophylaxis and implications for performance of VCUG are based on currently available evidence. As with all American Academy of Pediatrics clinical guidelines, the recommendations will be reviewed routinely and incorporate new evidence, such as data from the Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) study.

**CONCLUSIONS:** Changes in practice include criteria for the diagnosis of UTI and recommendations for imaging. Pediatrics 2014;134(5):e139-150.

Culture >50K  
AND  
UA (+LE/nitrates OR  
WBC)

## TESTING

Two step method,  
using bag UA to  
screen is  
appropriate

## TREATMENT

Oral = IV  
Local resistance  
7-14 days

## FOLLOW-UP/IMAGING

Follow-up @ 48h  
RBUS



Case 1:  
5 month  
old male



Case 2:  
10 week  
old  
female



Case 3:  
2 yo  
female  
with  
recurrent  
UTI

## Case 3

- 2yo girl with previous febrile UTI in France
- Febrile illness since am
- Do we test?
- Do we image?
- If VUR → What do we do?







# GUIDELINE

American Academy  
of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN™

## No VCUG for first febrile UTI if RBUS is nml

VCUG is not recommended to be performed routinely after the first febrile UTI if RBUS is normal.

- ✓ Evidence quality: B
- ✓ Recommendation

Further evaluation should be conducted if there is a recurrence of febrile UTI.

- ✓ Evidence quality: X
- ✓ Recommendation



Children's National™

# VUR: To Treat or To Not Treat

Evidence from the RIVUR Trial

Randomized Intervention for  
Children with VesicoUreteral Reflux

# *The* NEW ENGLAND JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

JUNE 19, 2014

VOL. 370 NO. 25

## Antimicrobial Prophylaxis for Children with Vesicoureteral Reflux


The RIVUR Trial Investigators\*



Children's National™

# RIVUR Trial

- 2-year randomized, double blind, placebo controlled trial



# Patient Characteristics

Median age  
12 months

92% girls


8% boys  
(63% uncirc)

80% had  
grades II or III  
reflux

56% BBD



# Study Outcomes



Recurrent UTI




Renal Scarring



Abx Resistance

# Decreased recurrences of UTI



No. at Risk

TMP-SMZ	302	270	252	244	128
Placebo	305	253	234	214	98

# No Change in Renal Scarring

NO

Difference Overall

---

- Prophylaxis 11.9%, Placebo 10.2% ( $p=0.55$ )

NO

Difference in Severe Renal Scarring

---

- Prophylaxis 4.8%, Placebo 2.6% ( $p=0.37$ )

NO

Difference in New Renal Scarring

---


- Prophylaxis 8.2%, Placebo 8.4% ( $p=0.94$ )



# Greater Antibiotic Resistance

- E.Coli from stool culture →
  - Resistance to TMP/SMZ was greater in treatment group, but not statistically significant
- 1<sup>st</sup> recurrent UTI with E.Coli →
  - Resistance to TMP/SMZ was greater in treatment group ( $p < 0.0001$ )

# Debate continues



## DIAGNOSIS

### CLINICAL PRACTICE GUIDELINE

## Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months

ADDITIONAL INFORMATION FROM THE AMERICAN ACADEMY OF PEDIATRICS  
COMMITTEE ON QUALITY IMPROVEMENT AND MANAGEMENT

#### KEY WORDS

urinary tract infection, urinary tract, urinary tract infection, urinary tract infection, urinary tract infection

#### ABBREVIATIONS

AAFP = American Academy of Pediatrics  
AAP = American Academy of Pediatrics  
ACU = American College of Urology  
AUA = American Urological Association  
AUA = American Urological Association  
AUA = American Urological Association  
AUA = American Urological Association  
AUA = American Urological Association

The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management. The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management. The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management.

The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management. The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management.

The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management. The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management.

The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management. The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management.

The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management. The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management.

The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management. The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management.

The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management. The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management.

The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management. The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management.

The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management. The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management.

The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management. The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management.

The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management. The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management.

The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management. The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management.

The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management. The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management.

The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management. The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management.

The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management. The guideline is a summary of a guideline developed by the American Academy of Pediatrics and the American Academy of Pediatrics Committee on Quality Improvement and Management.

**OBJECTIVE:** To revise the American Academy of Pediatrics practice parameter regarding the diagnosis and management of initial urinary tract infections (UTIs) in febrile infants and young children.

**METHODS:** Analysis of the medical literature published since the last version of the guideline was supplemented by analysis of data provided by authors of recent publications. The strength of evidence supporting each recommendation and the strength of the recommendations were assessed and graded.

**RESULTS:** Diagnosis is made on the basis of the presence of pyuria and at least 5000 colonies per mL of a single uropathogenic organism in an appropriately collected specimen of urine. After 2 to 4 days of antimicrobial treatment, close clinical follow-up monitoring should be maintained to permit prompt diagnosis and treatment of recurrent infections. Ultrasonography of the kidneys and bladder should be performed to detect urinary tract abnormalities. Data from the most recent studies do not support the use of antimicrobial prophylaxis to prevent febrile recurrent UTIs in infants without vesicoureteral reflux (VUR) or with grade I to IV VUR. Therefore, a voiding cystourethrogram (VCUG) is not recommended routinely after the first UTI. VCUG is indicated if renal and bladder ultrasonography reveals hydronephrosis, scarring, or other findings that would suggest either high-grade VUR or obstructive uropathy and in other atypical or complex clinical circumstances. VCUG should also be performed if there is a recurrence of a febrile UTI. The recommendations in this guideline do not indicate an exclusive course of treatment or serve as a standard of care; variations may be appropriate. Recommendations about antimicrobial prophylaxis and implications for performance of VCUG are based on currently available evidence. As with all American Academy of Pediatrics clinical guidelines, the recommendations will be reviewed routinely and incorporate new evidence, such as data from the Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) study.

**CONCLUSIONS:** Changes in this report include criteria for the diagnosis of UTI and recommendations for imaging. Pediatrics 2011;127:1250-1261.

Culture >50K  
AND  
UA (+LE/nitrates OR  
WBC)

Two step method,  
using bag UA to  
screen is  
appropriate

Oral = IV  
Local resistance  
7-14 days  
No prophylaxis

Follow-up @ 48h  
Not better - RBUS  
VCUG only if abnl  
RBUS or second UTI

## TREATMENT

## FOLLOW-UP/IMAGING

# Future Directions

- Due for revision of AAP guidelines
- Novel POC testing; non-invasive testing
- Smart diapers

# References

- AAP Clinical Practice Guideline:  
*Pediatrics*. 2011
  - <http://pediatrics.aappublications.org/content/early/2011/08/24/peds.2011-1330>
- AAP Webinar by Kenneth Roberts:
  - [http://www2.aap.org/pcorss/webinars/pco/AAP%20Webinar\\_UTI-Roberts-Final.ppt](http://www2.aap.org/pcorss/webinars/pco/AAP%20Webinar_UTI-Roberts-Final.ppt)

# **SUMMARY: 2011 AAP GUIDELINE FOR DIAGNOSIS AND MANAGEMENT OF UTIS IN FEBRILE INFANTS**

June 20, 2016



- **Inclusion**: Infant 2-24 mo with unexplained fever(  $> 38^{\circ}\text{C}$ )
  - Rate of UTI:  $\sim 5\%$
  - Rate of scarring higher than older children
- **Exclusion**: neurologic or anatomic abnormality known to be associated with recurrent UTI or renal damage

## DIAGNOSIS: 2011 AAP Guidelines

Specimen collection for urine culture must be catheterization or suprapubic aspiration

Risk stratification based on bag urinalysis and if positive then catheterize or suprapubic tap for culture

Diagnosis established with both suggestive of infection:

1. Urinalysis suggestive of infection
2. Culture with >50K CFU

**Strong**

**Recommend**



**Children's National**™



## MANAGEMENT: 2011 AAP Guidelines

YES – oral and parenteral abx equal efficacy

YES – 7 to 14 days of antimicrobial therapy

YES – RBUS: Febrile infants with UTIs should undergo renal and bladder sonography (RBUS)

IF ill and not improving then within first 48 hours

IF improving then, if done, better done > 48 hours

NO – VCUG after first febrile UTI

YES – VCUG after second UTI or if abnormal RBUS

YES – Once documented febrile UTI, instruct parents to return within 48 hours for another febrile illness

**Strong**

**Recommend**



**Children's National**™

# Changes from previous UTI Guidelines

- Diagnosis:
  - Abnormal urinalysis + positive culture (need both)
  - Positive culture is  $\geq 50\text{K CFU/mL}$
  - Assessment of likelihood of UTI
- Treatment:
  - Oral as effective as parenteral
- Imaging:
  - VCUG not routinely recommended after first febrile UTI
- Follow-up:
  - Emphasis on urine testing with subsequent febrile illnesses




# ALGORITHMS

June 20, 2016




**Children's National**™

**Figure 2.** Diagnostic Algorithm for Febrile Male Infants Aged 3 to 24 Months Suspected of Having a UTI




UTI indicates urinary tract infection; LR, likelihood ratio.

**Figure 3.** Diagnostic Algorithm for Febrile Female Infants Aged 3 to 24 Months Suspected of Having a UTI



UTI indicates urinary tract infection; LR, likelihood ratio.

**Figure 4.** Diagnostic Algorithm for Verbal Children Older Than 24 Months With Urinary or Abdominal Symptoms



UTI indicates urinary tract infection; LR, likelihood ratio.